Last reviewed · How we verify
Dothiepin (Dosulepin)
At a glance
| Generic name | Dosulepin |
|---|---|
| Sponsor | All India Institute of Medical Sciences, Bhubaneswar |
| Drug class | Tricyclic Antidepressants |
| Target | Histamine H1 receptor |
| Modality | Small molecule |
| Therapeutic area | Neuroscience |
| Phase | FDA-approved |
Approved indications
- Major depressive disorder
Common side effects
Drug interactions
- High Risk QT Prolonging Agents
Key clinical trials
- Effect of Venlafaxine Versus Dosulepin in Pain Predominant Somatic Symptom Disorder (PHASE4)
- Comparative Responses to 15 Different Antidepressants in Major Depressive Disorder
- Study of the Effect of Antidepressant Drugs on Neurotrophic Factors in Patients With Depression
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Dothiepin CI brief — competitive landscape report
- Dothiepin updates RSS · CI watch RSS
- All India Institute of Medical Sciences, Bhubaneswar portfolio CI